

20 December 2024

**BELLUSCURA PLC**  
("Belluscura" or the "Company")

**Appointment of Allenby Capital as Joint Broker**

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, is pleased to announce the appointment of Allenby Capital Limited as the Company's Joint Broker with immediate effect.

**For further information please contact:**

**Belluscura plc**  
Adam Reynolds, Chairman  
Robert Rauker, CEO  
Simon Neicheril, Chief Financial Officer

Tel: +44 (0)20 3128 8100

**SPARK Advisory Partners Limited**  
**Nominated Adviser**  
Neil Baldwin / Jade Bayat

Tel: +44 (0)20 3368 3550

**Dowgate Capital Limited**  
**Joint Broker**  
James Serjeant / Colin Clime (Sales and Corporate Broking)  
Russell Cook / Nicholas Chambers (Corporate Finance)

Tel: +44 (0)20 3903 7715

**Allenby Capital Ltd**  
**Joint Broker**  
Guy McDougall / Amrit Nahal (Sales and Corporate Broking)  
Jeremy Porter / Lauren Wright (Corporate Finance)

Tel: +44 (0)20 3328 5656

**MHP**  
**Financial PR & Investor Relations**  
Katie Hunt/Matthew Taylor

Tel: +44 (0)20 3128 8100  
email: [belluscura@mhpgroup.com](mailto:belluscura@mhpgroup.com)

**About Belluscura plc** (<https://ir.belluscura.com/>)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPTMBATMTBTBPI